All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Benjamin Derman, University of Chicago, Chicago, US. We asked, What are the main improvements in next-generation chimeric antigen receptor (CAR) T-cell products?
What are the main improvements in next-generation CAR T-cell products?
In this video, Derman considers multiple abstracts1–3 presented at ASH 2022 on studies that aim to improve CAR T-cell products, including the development of CAR T-cell therapies that can interact simultaneously with multiple targets, such as BCMA and CD19. Derman also discusses the possibility of reducing turnaround times by optimizing the manufacturing process, as well as developing CAR T‑cell products that can interact with new targets such as GPRC5D. Improvements in the persistence and immune tolerance of CAR T-cell therapies and initiating therapy in earlier lines are also considered.
Subscribe to get the best content related to multiple myeloma delivered to your inbox